This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

, 378 (15), 1444-1453

2018 Apr 12

The FDA Breakthrough-Drug Designation - Four Years of Experience

Jonathan J Darrow¹, Jerry Avorn¹, Aaron S Kesselheim¹

Affiliations

PMID: 29641970
DOI: 10.1056/NEJMhpr1713338

The FDA Breakthrough-Drug Designation - Four Years of Experience

Jonathan J Darrow et al. N Engl J Med. 2018

, 378 (15), 1444-1453

Authors

Jonathan J Darrow¹, Jerry Avorn¹, Aaron S Kesselheim¹

Affiliation

¹ From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.

PMID: 29641970
DOI: 10.1056/NEJMhpr1713338

Similar articles

New FDA breakthrough-drug category--implications for patients.
Darrow JJ, Avorn J, Kesselheim AS. Darrow JJ, et al. N Engl J Med. 2014 Mar 27;370(13):1252-8. doi: 10.1056/NEJMhle1311493. N Engl J Med. 2014. PMID: 24670173 No abstract available.
Notification vs approval.
Novack GD. Novack GD. Ocul Surf. 2007 Jul;5(3):255-8. doi: 10.1016/s1542-0124(12)70616-x. Ocul Surf. 2007. PMID: 17660899 Review. No abstract available.
FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR. Rossen BR. Food Drug Law J. 2009;64(1):183-223. Food Drug Law J. 2009. PMID: 19998746
Breakthrough-Therapy Designation - An FDA Perspective.
Corrigan-Curay J, McKee AE, Stein P. Corrigan-Curay J, et al. N Engl J Med. 2018 Apr 12;378(15):1457-1458. doi: 10.1056/NEJMc1801222. N Engl J Med. 2018. PMID: 29641963 No abstract available.
The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG, Albericio F. de la Torre BG, et al. Molecules. 2018 Feb 27;23(3):533. doi: 10.3390/molecules23030533. Molecules. 2018. PMID: 29495494 Free PMC article. Review.

See all similar articles

Cited by 5 articles

FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
Leo CP, Hentschel B, Szucs TD, Leo C. Leo CP, et al. Cancers (Basel). 2020 Feb 13;12(2):437. doi: 10.3390/cancers12020437. Cancers (Basel). 2020. PMID: 32069837 Free PMC article.
Improving the odds of drug development success through human genomics: modelling study.
Hingorani AD, Kuan V, Finan C, Kruger FA, Gaulton A, Chopade S, Sofat R, MacAllister RJ, Overington JP, Hemingway H, Denaxas S, Prieto D, Casas JP. Hingorani AD, et al. Sci Rep. 2019 Dec 11;9(1):18911. doi: 10.1038/s41598-019-54849-w. Sci Rep. 2019. PMID: 31827124 Free PMC article.
Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.
Herder M. Herder M. Milbank Q. 2019 Sep;97(3):820-857. doi: 10.1111/1468-0009.12413. Epub 2019 Aug 12. Milbank Q. 2019. PMID: 31407412
Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
Goring S, Taylor A, Müller K, Li TJJ, Korol EE, Levy AR, Freemantle N. Goring S, et al. BMJ Open. 2019 Feb 27;9(2):e024895. doi: 10.1136/bmjopen-2018-024895. BMJ Open. 2019. PMID: 30819708 Free PMC article.
Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?
Shepshelovich D, Amir E. Shepshelovich D, et al. Oncotarget. 2018 Jul 24;9(57):30942-30943. doi: 10.18632/oncotarget.25799. eCollection 2018 Jul 24. Oncotarget. 2018. PMID: 30123417 Free PMC article. No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.

Feedback